Publish Time: 2026-09-18 Origin: Site
Serum and plasma are not two outputs created by two different RPM settings. Their processing paths are already different before the centrifuge starts.
Serum preparation begins with a sample that must reach the appropriate clotting state before centrifugation.
Plasma preparation starts from anticoagulated blood. The acceptable residual cell or platelet content depends on the downstream method.
“Serum” and “plasma” are specimen categories, not complete centrifuge programs. The usable method is defined by the tube, specimen state, downstream requirement, RCF, time, temperature and deceleration behavior.
Different blood collection tubes may use different additives, separator materials, dimensions and processing requirements. Even tubes that ultimately produce serum or plasma do not automatically share the same clotting time, RCF, run time, temperature or braking condition.
Serum preparation includes a biological step before centrifugation: clot formation. If a sample enters the centrifuge before it reaches the state required by the tube instructions and laboratory method, simply increasing speed or extending the run does not convert an incomplete preanalytical process into a valid serum workflow.
Residual fibrin, continued clot formation or incomplete separation may still affect the sample after the rotor stops. The centrifuge therefore controls separation only after the specimen is ready for centrifugation.
Plasma is prepared from anticoagulated blood, but “plasma” does not describe one universal quality target. Some downstream methods tolerate more residual cellular material than others, while other workflows may require low residual platelets or additional processing. The successful endpoint is plasma that meets the requirement of the downstream examination.
Published clinical and research methods use different combinations of centrifugal force, time and temperature because the conditions belong to the specific tube and analytical method—not to the words “serum” or “plasma.”
| Decision Layer | Serum | Plasma |
|---|---|---|
| Pre-spin state | Required clot formation has occurred. | Blood remains anticoagulated. |
| Separation target | Liquid phase separated from clot/cellular material. | Liquid phase separated from cells to the quality required by the downstream method. |
| Typical risk | Incomplete clotting, residual fibrin, unstable separator interface. | Residual cells/platelets and unsuitable anticoagulated specimen quality. |
| Parameter source | Tube instructions + validated laboratory method. | Tube instructions + downstream test requirement + validated method. |
Two centrifuges running at the same RPM can produce different centrifugal force if their rotor radii differ.
When a tube or method specifies ×g, copying only the old RPM value to another rotor can change the actual specimen-processing condition.
If an older SOP records only RPM, a method transfer should first recover or calculate the original RCF from the original rotor geometry before selecting an equivalent setting on the new centrifuge.
Even when two rotors can achieve the same RCF, they may position the tube differently during the run and produce a different sediment or interface geometry. This matters when the post-spin interface itself affects sample handling.
Tubes move toward a horizontal position during operation. For many routine blood-tube workflows, this can create a flatter interface between liquid and sediment or separator material, simplifying downstream sampling.
Fixed-angle loading changes the direction and position of sedimentation. It can be suitable when the exact tube and workflow have been validated, but it should not be assumed equivalent solely because the RCF matches.
In tubes containing separator material, centrifugation must do more than produce a clear upper liquid layer. The separator also has to migrate to the intended position and form a stable barrier between phases.
Deceleration continues to influence the specimen after maximum speed has ended. Some workflows may require gentler deceleration to protect a fragile interface or reduce remixing. Other validated tube workflows can use faster braking without compromising the specimen.
Rapid deceleration can disturb loosely separated material in sensitive workflows.
Using the slowest possible deceleration when it is not required can reduce throughput without adding sample-quality benefit.
Braking should be defined by the specific tube and downstream method, not by a universal rule.
Serum does not universally require low-temperature centrifugation, and plasma does not universally require room-temperature centrifugation. Temperature belongs to the specific method.
When the workflow requires controlled temperature, the equipment must reproduce that condition. When temperature is not a critical method variable, refrigeration does not automatically improve separation quality. See the GlanLab Refrigerated vs Non-Refrigerated Centrifuge guide for the temperature-selection framework.
Additive, separator, geometry and relevant instructions.
Serum, plasma or a more specific plasma-quality target.
Use the specified centrifugal force rather than copying RPM between rotors.
Use the validated duration and define how timing is interpreted.
Record temperature when it is part of the validated method.
Store the run behavior when it can affect the final interface.
GlanLab YT5A provides up to 5,000 rpm and 4,730 ×g, with multiple swing-out rotor configurations for routine blood collection tubes and programmable acceleration/deceleration profiles.
The useful procurement question is not simply whether the centrifuge “can process blood.” It is whether the laboratory's actual tube format, required RCF, rotor geometry, batch size and braking profile can be matched to a validated program.
Additive, separator, dimensions or tube instructions may change the valid processing condition.
Radius, sedimentation geometry and post-spin interface can change even when nominal RCF is matched.
Do not copy an old RPM setting without confirming equivalent RCF and rotor geometry.
Temperature can affect the specimen and, in some workflows, separation behavior.
Deceleration behavior can alter the final interface or residual particulate content.
A specimen still called “plasma” may need a different residual platelet or cellular profile.
Visual separation can confirm that major phases have separated, but it cannot by itself establish that serum or plasma meets the downstream analytical requirement.
| What May Still Matter After a Visually Successful Spin | Why It Matters |
|---|---|
| Residual cells | May influence downstream analytical quality or stability. |
| Residual platelets | Can be critical in plasma workflows with stricter platelet requirements. |
| Residual fibrin | May indicate incomplete serum preparation or later clot formation risk. |
| Hemolysis | Can affect multiple downstream measurements even when the liquid phase looks clear. |
| Separator barrier quality | Determines whether the liquid fraction remains reliably isolated from underlying material. |
Clarify the required specimen and downstream quality requirement.
Use current tube instructions rather than a generic blood-tube assumption.
Use the validated force and duration required by the workflow.
Check both centrifugal force and the post-spin interface produced by the rotor.
Only use these conditions when they are part of the validated method.
Choose the centrifuge and rotor that can reproduce the entire workflow consistently.
Serum and plasma may both appear as a clear upper liquid phase after centrifugation, but they begin from different sample states and can have different downstream quality requirements.
A professional centrifugation method therefore does not begin by asking for a “standard serum RPM” or “standard plasma time.”
It begins with the exact tube and analytical target, then defines RCF, time, rotor geometry, temperature and deceleration as one controlled workflow.